FDA Allows IMPLANT 3 Trial to Begin Geneva, Switzerland and Boston, MA – October 31, 2019 – ObsEva SA (NASDAQ: OBSV…
Month: October 2019
ObsEva SA to Present Model-Based Analysis Supporting Clinical Use of Linzagolix at Doses Not Requiring Hormonal Add back Therapy
13th European Society of Gynecology (ESG) Congress: October 16-19 in Vienna, Austria. Oral Presentation, Thursday, October 17 at 11:45 a.m….
ObsEva SA to Present New Clinical Data on its Lead Compounds Nolasiban and Linzagolix at the 75th Annual ASRM Meeting in Philadelphia, PA
Oral Session Title: ART Offspring Monday, October 14, 2019 10:45 am-12:15 pm Eastern Daylight Time (EDT) Abstract O-16 –…
ObsEva SA to Present Model-Based Analysis Supporting Clinical Use of Linzagolix at Doses Not Requiring Hormonal Add back Therapy
Once-daily oral Linzagolix doses of 75 mg and 100 mg without hormonal add-back therapy could lead to symptom relief of…
ObsEva SA to Present New Clinical Data on its Lead Compounds Nolasiban and Linzagolix at the 75th Annual ASRM Meeting in Philadelphia, PA
Geneva, Switzerland and Boston, MA – October 9, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage…
Babies Born Following Administration of Nolasiban Before Embryo Transfer (ET) After IVF: Neonatal and Infant Development Outcomes From a Double-Blind, Placebo-Controlled, Clinical Trial
Humberstone A., Terrill P., Macgregor L., Loumaye E.
ASRM 2019 Scientific Congress & Expo, 12-16 October 2019, Philadelphia, PA
Fertility and Sterility Vol. 112, No. 3, Supplement, September 2019. Abstract on pages e7-e8.
Long Term Treatment of Endometriosis Associated Pain (EAP) With Linzagolix: Efficacy and Safety After 12 Months of Treatment
Taylor R., Bestel E., Gotteland JP., Lecomte V., Dubouloz R., Terrill P., Humberstone A., Loumaye E.
ASRM 2019 Scientific Congress & Expo, 12-16 October 2019, Philadelphia, PA
Fertility and Sterility Vol. 112, No. 3, Supplement, September 2019. Abstract on page e323.